Pieris Pharmaceuticals, Inc. Aktie News

FDA Orphan Products Grants are awarded based on rigorous scientific and technical review by rare disease and regulatory experts

Ms. Kline to lead Palvella's commercial buildout for planned standalone U.S. launch of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations, a serious, rare, and lifelong genetic disease affecting an estimated more than 30,0000 patients in the U.S., if approved Under Kline's leadership at Dompé, Oxervate®, a first-in-disease topical therapy for rare d...

Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs) has exceeded enrollment target of 40 patients; enrollment expected to close in June 2025

WAYNE, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its first quarter 2025 financial results on ...

WAYNE, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, announced today that the Co...

Quantitative analysis of medical claims indicates an estimated 44,553 to 92,967 diagnosed U.S. patients with lymphatic malformations (LMs) with cutaneous involvement

Fifth issued patent in the U.S. for QTORIN™ rapamycin with anticipated patent life extending into 2038 QTORIN™ rapamycin has the potential to be the first approved therapy and standard of care for microcystic lymphatic malformations in the U.S. WAYNE, Pa., April 22, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutica...

Presentation highlighted the recent expansion of the Phase 3 SELVA trial to include children 3 to 5 years old Presentation reviewed clinically and statistically significant Phase 2 results and the design of the ongoing Phase 3 SELVA trial Top-line results from SELVA remain on track for the first quarter of 2026 QTORIN™ 3.9% rapamycin anhydrous gel has the potential to be the first approved ther...